Marjolaine Gauthier-Loiselle

Marjolaine Gauthier-Loiselle

Auto-generated profile, based on publicly available information

Marjolaine Gauthier-Loiselle

Health Economics and Outcomes Research, Analysis Group, Inc., Montreal, Canada

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 August 2018 in Cardiovascular Diabetology
Verified
Journal Article
Open access
PDF file
JYJames B. Young
James B. Young
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
RBRobert A. Bailey
Robert A. Bailey
AMAmeur M. Manceur
Ameur M. Manceur
PLPatrick Lefebvre
Patrick Lefebvre
CWCarol H. Wysham
Carol H. Wysham
There exist several predictive risk models for cardiovascular disease (CVD), including some developed specifically for patients with type 2 diabetes mellitus (T2DM). However, the models developed for a diabetic population are based on information derived from medical records or laboratory results, which are not typically available to entities like payers or quality of care organizations. The objective of this study is to develop and validate models predicting the risk of cardiovascular events in patients with T2DM based on medical insurance claims data. Patients with T2DM aged 50 years or older were identified from the Optum™ Integrated Real World Evidence Electronic Health Records and Claims de-identified database (10/01/2006–09/30/2016). Risk factors were assessed over a 12-month baseline period and cardiovascular events were monitored from the end of the baseline period until end of data availability, continuous enrollment, or death. Risk models were developed using logistic regressions separately for patients with and without prior CVD, and for each outcome: (1) major adverse cardiovascular events (MACE; i.e., non-fatal myocardial infarction, non-fatal stroke, CVD-related death); (2) any MACE, hospitalization for unstable angina, or hospitalization for congestive heart failure; (3) CVD-related death. Models were developed and validated on 70% and 30% of the sample, respectively. Model performance was assessed using C-statistics. A total of 181,619 patients were identified, including 136,544 (75.2%) without prior CVD and 45,075 (24.8%) with a history of CVD. Age, diabetes-related hospitalizations, prior CVD diagnoses and chronic pulmonary disease were the most important predictors across all models. C-statistics ranged from 0.70 to 0.81, indicating that the models performed well. The additional inclusion of risk factors derived from pharmacy claims (e.g., use of antihypertensive, and use of antihyperglycemic) or from medical records and laboratory measures (e.g., hemoglobin A1c, urine albumin to creatinine ratio) only marginally improved the performance of the models. The claims-based models developed could reliably predict the risk of cardiovascular events in T2DM patients, without requiring pharmacy claims or laboratory measures. These models could be relevant for providers and payers and help implement approaches to prevent cardiovascular events in high-risk diabetic patients.

18 February 2020 in BMC Health Services Research
Verified
Journal Article
Open access
PDF file
MCMartin Cloutier
Martin Cloutier
AMAmeur M. Manceur
Ameur M. Manceur
AGAnnie Guerin
Annie Guerin
MAMyrlene Sanon Aigbogun
Myrlene Sanon Aigbogun
DODorothee Oberdhan
Dorothee Oberdhan
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
Background: Autosomal dominant polycystic kidney disease (ADPKD) is one of the most common inherited kidney diseases characterized by progressive development of renal cysts and numerous extra-renal manifestations, eventually leading to kidney failure. Given its chronic and progressive nature, ADPKD is expected to carry a substantial economic burden over the course of the disease. However, there is a paucity of evidence on the impact of ADPKD from a societal perspective. This study aimed to estimate the direct and indirect costs associated with ADPKD in the United States (US). Methods: A prevalence-based approach using data from scientific literature, and governmental and non-governmental organizations was employed to estimate direct healthcare costs (i.e., medical services, prescription drugs), direct non-healthcare costs (i.e., research and advocacy, donors/recipients matching for kidney transplants, transportation to/from dialysis centers), and indirect costs (i.e., patient productivity loss from unemployment, reduced work productivity, and premature mortality, caregivers’ productivity loss and healthcare costs). The incremental costs associated with ADPKD were calculated as the difference between costs incurred over a one-year period by individuals with ADPKD and the US population. Sensitivity analyses using different sources and assumptions were performed to assess robustness of estimates and account for variability in published estimates. Results: The estimated total annual costs attributed to ADPKD in 2018 ranged from $7.3 to $9.6 billion in sensitivity analyses, equivalent to $51,970 to $68,091 per individual with ADPKD. In the base scenario, direct healthcare costs accounted for $5.7 billion (78.6%) of the total $7.3 billion costs, mostly driven by patients requiring renal replacement therapy ($3.2 billion; 43.3%). Indirect costs accounted for $1.4 billion (19.7%), mostly driven by productivity loss due to unemployment ($784 million; 10.7%) and reduced productivity at work ($390 million; 5.3%). Total excess direct non-healthcare costs were estimated at $125 million (1.7%). Conclusions: ADPKD carries a considerable economic burden, predominantly attributed to direct healthcare costs, the majority of which are incurred by public and private healthcare payers. Effective and timely interventions to slow down the progression of ADPKD could substantially reduce the economic burden of ADPKD.

29 August 2017 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
RMRichard T. Maziarz
Richard T. Maziarz
YHYanni Hao
Yanni Hao
AGAnnie Guerin
Annie Guerin
GGGeneviève Gauthier
Geneviève Gauthier
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
LELamis Eldjerou
Lamis Eldjerou
This study describes short-term and long-term healthcare resource utilization (HRU) and costs following an allogeneic hematopoietic stem cell transplant (HSCT) in adult patients with diffuse large B-cell lymphoma (DLBCL) in a real-world setting. Among 101 patients with DLBCL receiving an allogeneic HSCT, HRU and direct healthcare costs for up to three years after the allogeneic HSCT are described. HRU and costs were substantial, with the most intensive HRU and highest healthcare costs observed during the first year after HSCT (38 inpatient days; 68 days with office visits and average healthcare costs of $455,741). Although HRU and costs decreased over time, they remained high even in the third year after HSCT (four inpatient days; 27 days with office visits and average healthcare costs of $72,957). Overall, this study showed that the economic burden following an allogeneic HSCT in DLBCL patients is significant.

30 September 2022 in Current Medical Research and Opinion
Verified
Journal Article
Open access
JSJeff Schein
Jeff Schein
MCMartin Cloutier
Martin Cloutier
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
RBRebecca Bungay
Rebecca Bungay
AGAnnie Guerin
Annie Guerin
ACAnn Childress
Ann Childress
Describe symptoms associated with ADHD/treatment-related adverse side effects among adults with ADHD in the US and assess their impact on quality of life (QoL) and work productivity.An online surve...

7 March 2022 in Kidney Medicine
Verified
Journal Article
Open access
SMSteven N. Michalopoulos
Steven N. Michalopoulos
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
MAMyrlene Sanon Aigbogun
Myrlene Sanon Aigbogun
ESElizabeth Serra
Elizabeth Serra
RBRebecca Bungay
Rebecca Bungay
JWJay Wish
Jay Wish
Chronic kidney disease (CKD) has a far-reaching impact on both patients and care partners, which can be further compounded by frequent complications such as anemia. This study assessed the burden experienced by patients with CKD and the care partners of patients with CKD, with and without anemia. Online survey. Adult patients with CKD and the care partners of adult patients with CKD living in the United States were recruited through the American Association of Kidney Patients and a third-party online panel (January 9, 2020-March 12, 2020). Patient and care partner characteristics, care received or provided; health-related quality of life, and work productivity. Descriptive statistics were reported separately based on the presence or absence of anemia. In total, 410 patients (anemia: n=190, no anemia: n=220) and 258 care partners (anemia: n=110, no anemia: n=148) completed the survey. Most patients reported receiving paid or unpaid care because of their health condition (anemia: 58.9%, no anemia: 50.9%), with an overall average of 14.2 and 11.3 h/wk among the anemia and no anemia patients, respectively. The care partners also reported providing numerous hours of care (anemia: 33.6 h/wk, no anemia: 38.0 h/wk), especially care partners living with their care recipient (anemia: 52.6 h/wk, no anemia: 42.8 h/wk). Among the patients, those with anemia reported a numerically lower average health-related quality of life (Functional Assessment of Cancer Therapy-Anemia score, anemia: 110.1; no anemia: 121.6). Most care partners reported a severe or very severe burden (Burden Scale for Family Caregivers-Short Version score≥15, anemia: 69.1%; no anemia: 58.8%). The work productivity impairment was substantial among employed patients (anemia: 44.9%, no anemia: 35.4%) and employed care partners (anemia: 47.9%, no anemia: 40.7%). The survey results may have been subject to selection and recall biases; moreover, the observational nature of the study does not allow for causal inferences. Patients with CKD and the care partners of patients with CKD experience a considerable burden, especially when anemia is present.

18 November 2023 in PharmacoEconomics - Open
Verified
Journal Article
Open access
PDF file
HDHilary M. DuBrock
Hilary M. DuBrock
HGHayley D. Germack
Hayley D. Germack
MGMarjolaine Gauthier-Loiselle
Marjolaine Gauthier-Loiselle
JLJörg Linder
Jörg Linder
ASAmbika Satija
Ambika Satija
RFRobert P. Frantz
Robert P. Frantz
Background The aim of this study was to assess health care resource utilization (HRU) and costs associated with delayed pulmonary arterial hypertension (PAH) diagnosis in the United States. Methods Eligible adults with newly diagnosed PAH from Optum’s de-identified Clinformatics® Data Mart Database (2016–2021) were assigned to mutually exclusive cohorts based on time between first PAH-related symptom and first PAH diagnosis (i.e., ≤12 months’ delay, >12 to ≤24 months’ delay, >24 months’ delay). All-cause HRU and health care costs per patient per month (PPPM) were assessed during the first year following diagnosis and compared across cohorts using regression analysis adjusted for baseline covariates. Sensitivity analyses were conducted to assess outcomes during all available follow-up post-diagnosis. Results Among 538 patients (mean age: 65.6 years; 60.6% female), 60.8% had ≤12 months’ delay, 23.4% had a delay of >12 to ≤24 months, and 15.8% had >24 months’ delay. Compared with ≤12 months, delays of >12 to ≤24 months and >24 months were associated with increased hospitalizations (incidence rate ratio [95% confidence interval]: 1.40 [1.11–1.71] vs 1.71 [1.29–2.12]) and outpatient visits (1.17 [1.06–1.30] vs 1.26 [1.08–1.41]). Longer delays were also associated with more intensive care unit (ICU) stays and 30-day readmissions. Diagnosis delays translated into excess costs PPPM of US$3986 [1439–6436] for >12 to ≤24 months and US$5366 [2107–8524] for >24 months compared with ≤12 months’ delay; increased hospitalization costs (US$3248 [1108–5135] and US$4048 [1401–6342], respectively) being the driver. Sensitivity analyses yielded similar trends. Conclusions Delayed PAH diagnosis is associated with significant incremental economic burden post-diagnosis, driven by hospitalizations including ICU stays and 30-day readmissions, highlighting the need for increased awareness and a potential benefit of earlier screening.